PNH in Focus: Neepaja Canjiradan Discusses Hemolysis, Diagnostic Clues, and Complement Inhibitor Therapy
Neepaja Canjiradan, a clinical pathologist at AVM Labs, posted on LinkedIn:
”Haematology series 17
Paroxysmal nocturnal Haemoglobinuria: The only condition where your urine says “Good Morning” darker than your coffee
On the Peripheral Smear
Hemolysis galore → bite cells, ghost cells, and the occasional schistocyte cameo.
Reticulocytosis – marrow working overtime like a resident on night duty.
Basically looks like “aftermath of a complement bar fight.”
In the Bone Marrow
Hypoplastic/aplastic in some, hyperplastic in others.
Erythroid hyperplasia = marrow screaming “I got this!” while clearly not.
Frequently hand-in-hand with aplastic anemia or MDS-PNH is never lonely.
Flow Cytometry (the Real MVP)
The mic-drop moment → loss of CD55 and CD59 on RBCs and granulocytes.
Forget the Ham test—flow cytometry is the Sherlock Holmes here.
Seeing that PNH clone pop up is equal parts diagnostic thrill and clinical reality check.
Treatment in a Nutshell
Big strides from IV infusions to oral therapies.
Complement inhibitors galore, but let the hematologists juggle the alphabet soup.
HSCT = still the only curative pathway.
Pathologist’s Humor Corner
PNH patients: “Why is my urine so dark in the morning?”
Pathologist: “Because your RBCs had a rough night.”
RBCs without CD55/CD59 → the ultimate example of what happens when you skip PPE.
Flow cytometry in PNH = Facebook relationship status: “It’s complicated.”
Bottom Line
Smear gives the clues,
Marrow shows the struggle,
Flow cytometry seals the deal.
PNH may be rare, but it keeps pathology exciting – diagnostics with just the right mix of science and sass.”
Stay updated with Hemostasis Today.
-
Sep 18, 2025, 06:50Fetal Hereditary TTP Featured in NEJM – Senior Author Nishant Rajendra Tiwari
-
Sep 17, 2025, 10:54Mitapivat Boosts ATP in Red Cells: Dr. William Aird on New Hope for Hemolytic Disorder
-
Sep 17, 2025, 08:16Superficial Vein Thrombosis Management: John Fanikos Shares Latest Review
-
Sep 17, 2025, 07:00Maha Othman - ''BIC 2025 is Without a Doubt a Remarkable Scientific Event — and I’m Excited for What Lies Ahead!''
-
Sep 16, 2025, 11:17Glenn Pierce: WHO Issues a Biannual Essential Medicines List
-
Sep 18, 2025, 07:00Rishabh Singh on NEJM Letter: FVIII Aurora Mutation Shows Increased Activity and Reduced APC Response
-
Sep 18, 2025, 02:25Flora Peyvandi Highlights 'Inflammatory Memory of Stem Cells' – New Insights for Hematologic Diseases
-
Sep 17, 2025, 16:32Endovascular Today: Dr. Eric Secemsky Analyzes Impact of Paclitaxel Pause on Peripheral Artery Disease Care
-
Sep 17, 2025, 16:28Haemnet Showcases Research on Severe Haemophilia A Patients Adapting to Emicizumab Therapy
-
Sep 17, 2025, 16:19Todd Villines: Coronary Artery Disease - A BIG Movement to Change
-
Sep 16, 2025, 14:59A New Era in Antiplatelet Therapy for CABG?
-
Sep 16, 2025, 07:44Artificial Blood Breakthrough in Japan: Long Shelf Life, No Type Matching, and a Purple Future
-
Sep 16, 2025, 02:44Wolfgang Miesbach Highlights First Inhibitor Case After Hemophilia A Gene Therapy (Giroctocogene Fitelparvovec)
-
Sep 12, 2025, 15:21Christian Schäfer: INR Self-Management Has Officially Been Given Class IA Status in the ESC Guidelines
-
Sep 9, 2025, 20:15Linking a Single Dominant Antibody to HIT: A Novel Study Led by Ishac Nazy, Donald Arnold, and John G. Kelton
-
Sep 18, 2025, 06:34'A New Era in Mechanical Thrombectomy?' – Sripal Bangalore Highlights SYMPHONY-PE IDE Study
-
Sep 17, 2025, 10:49Living with Glanzmann Thrombasthenia․ Eliza VanZweden’s Story of Resilience and Advocacy
-
Sep 17, 2025, 10:22Abdul Mannan: Turning Medical Podcasts into Active Learning with Structured Tools
-
Sep 17, 2025, 09:43Global Blood Supply Under Threat: David McIntosh Calls for Action to Support Transfusion Services
-
Sep 17, 2025, 09:08Coronary Arteries, Pericardial Cavity, and the Hidden Danger of Cardiac Tamponade During PCI-By Ahmed Ata